Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company using biomarkers and augmented intelligence to help physicians identify the source of chronic low back pain, has appointed Daniel Keefe as Commercial Director for the Western United States. The appointment, announced April 28, 2026, signals the company's commitment to expanding the clinical use of Nociscan, its cloud-based platform that noninvasively distinguishes painful from nonpainful lumbar discs.
Keefe brings more than 20 years of experience in medical device and healthcare technology sales, with leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, as Regional Sales Manager at Centinel Spine, he exceeded performance targets and delivered significant year-over-year growth across Northern California. His expertise includes building strategic relationships with surgeons and hospital leadership, launching new technologies, and expanding market presence in competitive environments.
"Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies," said Brent Ness, Chief Executive Officer of Aclarion. "His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S. and support broader clinical use of Nociscan."
The Western U.S. is a key strategic region for Aclarion, where the company has established a growing presence across academic institutions and high-volume private practice spine centers, supported by strong volume growth. The appointment reflects the increasing demand for Nociscan, which has seen triple-digit growth in utilization. An estimated 266 million people worldwide live with chronic low back pain, and Nociscan provides objective insights into the location of pain, demonstrating a 97% surgical success rate when all Nociscan-positive discs are treated.
"I'm excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community," Keefe said. "The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated. I look forward to working with physicians and spine centers across the Western U.S. to expand access to Nociscan and support its continued integration into clinical practice."
Nociscan is the first evidence-supported, cloud-based platform to noninvasively help physicians distinguish between painful and nonpainful discs by quantifying chemical biomarkers associated with disc pain. The platform uses magnetic resonance spectroscopy data from an MRI machine, processed with proprietary signal processing and augmented intelligence algorithms, to provide critical insights for optimizing treatment strategies. For more information on Nociscan, visit www.aclarion.com.
